Hígado graso (parte 2): enfoque clínico y tratamiento

Los pacientes con hígado graso son casi siempre asintomáticos, las aminotransferasas usualmente están elevadas dos a cinco veces el valor normal y son una causa importante de consulta inicial. Todas las imágenes pueden evidenciar el hígado graso y la biopsia hepática sigue siendo la prueba de oro para su diagnóstico. En cualquier paciente las pruebas no invasivas son una excelente alternativa a la biopsia para determinar el grado de fibrosis hepática y establecer en qué etapa de la fibrogénesis se encuentra. La pérdida de peso y el ejercicio son los pilares fundamentales del tratamiento indicado para todos los pacientes con sobrepeso u obesidad; se recomienda una pérdida de peso entre 5% y 10% del peso corporal y una dieta con restricción calórica de 500-1000 kcal/día, baja en grasas saturadas y rica en productos de la dieta mediterránea como fruta, pescado, verduras, frutos secos, aceite de oliva, entre otros. Hay otros tratamientos como las medidas farmacológicas y los procedimientos endoscópicos y quirúrgicos.

[1]  R. Gabbay,et al.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2022, Diabetologia.

[2]  Vinni Makin,et al.  The role of GLP-1 receptor agonists in managing type 2 diabetes , 2022, Cleveland Clinic Journal of Medicine.

[3]  M. Trauner,et al.  Current treatment of non‐alcoholic fatty liver disease , 2022, Journal of internal medicine.

[4]  L. Errington,et al.  The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis. , 2022, Clinical nutrition.

[5]  A. Singal,et al.  Safety and efficacy of dyslipidemia treatment in NAFLD Patients: a Meta-analysis of randomized controlled trials. , 2022, Annals of hepatology.

[6]  Feifei Mo,et al.  Effects of Bariatric Endoscopy on Non-Alcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Meta-Analysis , 2022, Frontiers in Endocrinology.

[7]  K. Kowdley,et al.  Non-Alcoholic Steatohepatitis Drug Development Pipeline: An Update. , 2022, Seminars in liver disease.

[8]  K. Cusi,et al.  American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). , 2022, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[9]  H. Randeva,et al.  SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection , 2022, International journal of molecular sciences.

[10]  A. Duarte-Rojo,et al.  Fatty Liver Disease: Diagnosis and Stratification. , 2021, Annual Review of Medicine.

[11]  M. Valasek,et al.  Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease , 2021, Therapeutic advances in gastroenterology.

[12]  C. Dietrich,et al.  Screening for nonalcoholic fatty liver disease-when, who and how? , 2021, World journal of gastroenterology.

[13]  V. de Lédinghen,et al.  NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF NON-ALCOHOLIC FATTY LIVER DISEASE. , 2021, Clinics and research in hepatology and gastroenterology.

[14]  M. Roden,et al.  Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis , 2021, Seminars in Liver Disease.

[15]  A. Acosta,et al.  Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review , 2021, Seminars in Liver Disease.

[16]  K. Watt,et al.  Risks and Rewards of Bariatric Surgery in Advanced Chronic Liver Diseases , 2021, Seminars in Liver Disease.

[17]  S. Zelber-Sagi.  Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations , 2021, Seminars in Liver Disease.

[18]  C. Thompson,et al.  Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  P. Schauer,et al.  Presence of Liver Steatosis Is Associated With Greater Diabetes Remission After Gastric Bypass Surgery , 2020, Diabetes Care.

[20]  V. de Lédinghen,et al.  Transient Versus Two‐Dimensional Shear‐Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD , 2020, Hepatology.

[21]  K. Cusi,et al.  Latin American Association for the Study of the Liver (ALEH) Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. , 2020, Annals of hepatology.

[22]  A. Gastaldelli,et al.  Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH , 2020, International journal of molecular sciences.

[23]  Z. Younossi,et al.  Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  K. Duffin,et al.  Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes , 2020, Diabetes Care.

[25]  A. Darzi,et al.  Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study. , 2020, European heart journal.

[26]  L. Castéra.  Non‐invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[27]  Michal Rein,et al.  The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. , 2019, Journal of hepatology.

[28]  M. Anvari,et al.  Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta‐analysis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  Rohit Loomba,et al.  Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[30]  U. Wisløff,et al.  Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study. , 2019, Progress in cardiovascular diseases.

[31]  Nik Raihan Nik Mustapha,et al.  Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus , 2019, Digestive Diseases and Sciences.

[32]  Antonio Felix Conde-Martin,et al.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. , 2018, Gastroenterology.

[33]  T. Pieber,et al.  A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin , 2018, Diabetes Care.

[34]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[35]  R. Bataller,et al.  Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. , 2018 .

[36]  Brian W. Anthony,et al.  Principles of ultrasound elastography , 2018, Abdominal Radiology.

[37]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[38]  X. Chi,et al.  Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis , 2017, PloS one.

[39]  Rohit Loomba,et al.  MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. , 2016, Journal of hepatology.

[40]  A. Sanyal,et al.  Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. , 2016, Clinics in liver disease.

[41]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[42]  K. Cusi.  Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions , 2016, Diabetologia.

[43]  T. Yamanaka,et al.  Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. , 2016, Gastroenterology.

[44]  M. Ali,et al.  American Society for Metabolic and Bariatric Surgery position statement on intragastric balloon therapy endorsed by the Society of American Gastrointestinal and Endoscopic Surgeons. , 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[45]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[46]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[47]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[48]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[49]  Mohammad Hassan Murad,et al.  Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[50]  S. Park,et al.  Radiologic evaluation of nonalcoholic fatty liver disease. , 2014, World journal of gastroenterology.

[51]  Julien Vergniol,et al.  Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease. , 2013, Radiology.

[52]  E. Bjornsson,et al.  Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. , 2013, Gastroenterology.

[53]  R. Pozzi Mucelli,et al.  Acoustic radiation force impulse of the liver. , 2013, World journal of gastroenterology.

[54]  B. Neuschwander‐Tetri,et al.  Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis , 2013, Alimentary pharmacology & therapeutics.

[55]  G. Ferraioli,et al.  Accuracy of real‐time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study , 2012, Hepatology.

[56]  Catriona A. Burdon,et al.  Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. , 2012, Journal of hepatology.

[57]  K. Lindor,et al.  The Spontaneous Course of Liver Enzymes and Its Correlation in Nonalcoholic Fatty Liver Disease , 2012, Digestive Diseases and Sciences.

[58]  D. Kleiner,et al.  Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research , 2012, Seminars in Liver Disease.

[59]  James E. Nelson,et al.  Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease , 2012, Hepatology.

[60]  R. Loomba,et al.  Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitis , 2012, Alimentary pharmacology & therapeutics.

[61]  G. Musso,et al.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials , 2012, Diabetologia.

[62]  Eliseo Guallar,et al.  Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis , 2011, Hepatology.

[63]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[64]  S. Horgan,et al.  Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. , 2011, Radiology.

[65]  Ying Sun,et al.  Performance of the aspartate aminotransferase‐to‐platelet ratio index for the staging of hepatitis C‐related fibrosis: An updated meta‐analysis , 2011, Hepatology.

[66]  E. Brunt,et al.  Histopathology of nonalcoholic fatty liver disease. , 2010, World journal of gastroenterology.

[67]  H. Conjeevaram,et al.  Meta‐analysis: insulin sensitizers for the treatment of non‐alcoholic steatohepatitis , 2010, Alimentary pharmacology & therapeutics.

[68]  B. Neuschwander‐Tetri,et al.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease , 2010, Hepatology.

[69]  G. Musso,et al.  A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease , 2010, Hepatology.

[70]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[71]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[72]  S. Caldwell,et al.  Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. , 2009, Journal of hepatology.

[73]  Riitta Parkkola,et al.  Nonalcoholic fatty liver disease: rapid evaluation of liver fat content with in-phase and out-of-phase MR imaging. , 2009, Radiology.

[74]  B. Neuschwander‐Tetri,et al.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease , 2008, Gut.

[75]  L. Schwartz,et al.  Preoperative radiographic assessment of hepatic steatosis with histologic correlation. , 2008, Journal of the American College of Surgeons.

[76]  A. Manduca,et al.  Assessment of hepatic fibrosis with magnetic resonance elastography. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[77]  J. Hoofnagle,et al.  The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis , 2007, Hepatology.

[78]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[79]  A. Lazenby,et al.  The Prevalence of Nonalcoholic Steatohepatitis is Greater in Morbidly Obese Men Compared to Women , 2006, Obesity surgery.

[80]  Sang Won Lee,et al.  Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. , 2006, Radiology.

[81]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[82]  C. Mottin,et al.  The Role of Ultrasound in the Diagnosis of Hepatic Steatosis in Morbidly Obese Patients , 2004, Obesity surgery.

[83]  R. Fisher,et al.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.

[84]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.